Rohit Bhatheja, MD
Cardiovascular Disease · Orlando, FLNPI 1912097627
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $182,100 of the $257,288 with a category attached, or 70.8%. It is spread thinly across 34 manufacturers, the largest accounting for just 22.3%. Reporting peaked in 2024 at $102,409 and has fallen 71.3% since, to $29,363 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 398 payments — averaging $646.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$57K
- Penumbra, Inc.$36K
- Abbott$35K
- Chiesi USA, Inc.$27K
- Cardiovascular Systems Inc.$25K
- Boston Scientific$18K
- plus $57K from 28 others
Across 153 payments — averaging $4175.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$381K
- Amgen$73K
- Novartis$64K
- Abbott$46K
- Penumbra, Inc.$44K
- Boston Scientific$12K
- plus $19K from 3 others
What the payments were for
- Consulting fees$28,38011%
- Speaking & faculty fees$182,10071%
- Travel & lodging$29,81212%
- Food & beverage$16,9747%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 55 | $57,438 |
| Penumbra, Inc. | 50 | $36,297 |
| Abbott | 64 | $34,994 |
| Chiesi USA, Inc. | 18 | $27,361 |
| Cardiovascular Systems Inc. | 41 | $25,402 |
| Boston Scientific | 31 | $18,441 |
| Amgen | 24 | $17,103 |
| Novartis | 25 | $9,455 |
| Philips North America LLC | 6 | $9,239 |
| EKOS Corporation | 2 | $7,500 |
| Lilly USA, LLC | 7 | $6,484 |
| Terumo Medical Corporation | 2 | $2,886 |
| Medtronic | 15 | $1,998 |
| Shockwave Medical, Inc | 5 | $431 |
| Abiomed | 3 | $421 |
| Cvrx, Inc. | 6 | $403 |
| Siemens Medical Solutions USA, Inc. | 1 | $175 |
| Merck | 8 | $171 |
| Novo Nordisk | 4 | $166 |
| Edwards Lifesciences | 1 | $145 |
| E.r. Squibb & Sons, L.L.C. | 6 | $122 |
| Biotronik Inc. | 1 | $90 |
| Esperion Therapeutics, Inc. | 4 | $81 |
| Livanova USA, Inc. | 1 | $80 |
| Pfizer | 3 | $62 |
| AstraZeneca | 2 | $57 |
| Bayer | 3 | $50 |
| Myocardial Solutions, Inc. | 1 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $43 |
| Stryker | 1 | $32 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Angiodynamics, Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$62,735
- Indigo System$29,756
- KENGREAL$27,294
- Diamondback Coronary$18,791
- Coronary Orbital Atherectomy System$17,523
- Repatha$16,821
- Spectranetics Undiv$8,798
- LEQVIO$8,741
- Xience V coronary stent system$8,419
- GENERAL VASCULAR ACCESS$7,602
- EKOSONIC$7,500
- Indigo$5,767
- DRAGONFLY OPSTAR$3,625
- OPTIS$3,600
- SURFLASH$2,750
- AMPLATZER$2,500
- MitraClip$2,158
- ESPRIT$1,465
- VenaSeal$1,299
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$330
How this compares
$257,288 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 364 | $408,146 |
| JardianceEmpagliflozin | 317 | $309,060 |
| Repatha SureclickEvolocumab | 247 | $252,648 |
| EntrestoSacubitril/Valsartan | 104 | $140,242 |
| XareltoRivaroxaban | 91 | $100,080 |
| Praluent PenAlirocumab | 58 | $55,969 |
| BrilintaTicagrelor | 56 | $55,070 |
| MultaqDronedarone Hcl | 31 | $49,350 |
| Ranolazine ErRanolazine | 332 | $38,948 |
| NexletolBempedoic Acid | 42 | $38,387 |
| VerquvoVericiguat | 22 | $33,979 |
| NexlizetBempedoic Acid/Ezetimibe | 31 | $26,029 |
| Repatha PushtronexEvolocumab | 30 | $25,914 |
| VascepaIcosapent Ethyl | 26 | $16,511 |
| CorlanorIvabradine Hcl | 25 | $15,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $62 | $408,146364 claims |
| Boehringer IngelheimJardiance | $57,438 | $309,060317 claims |
| NovartisEntresto | $9,455 | $140,242104 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $81 | $64,41673 claims |
| AstraZenecaBrilinta | $57 | $55,07056 claims |
| MerckVerquvo | $171 | $33,97922 claims |
| AmgenCorlanor | $17,103 | $15,28825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Orlando
- Nirav RavalOrlando$176K
- James TarverOrlando$112K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.